Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to ...

PMGC Holdings Inc. (NASDAQ: ELAB) shares are trading higher Friday after the company announced that its subsidiary, ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Hers shares information about the average weight for women in the U.S., what women believe the ideal weight is, and the ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Ozempic being a household name, GLP-1 receptor agonists (GLP-1RAs), a class of medications have garnered significant ...

Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 results along with program updates, progress in its GLP-1 trials, a capital ...